|本期目录/Table of Contents|

[1]杨艺虹,尹迪,张珩.波生坦的合成[J].武汉工程大学学报,2012,(12):1-3,7.[doi:103969/jissn16742869201212001]
 YANG Yi hong,YIN Di,ZHANG Heng.On synthesis of bosentan[J].Journal of Wuhan Institute of Technology,2012,(12):1-3,7.[doi:103969/jissn16742869201212001]
点击复制

波生坦的合成(/HTML)
分享到:

《武汉工程大学学报》[ISSN:1674-2869/CN:42-1779/TQ]

卷:
期数:
2012年12期
页码:
1-3,7
栏目:
化学与化学工程
出版日期:
2013-01-11

文章信息/Info

Title:
On synthesis of bosentan
文章编号:
16742869(2012)12000103
作者:
杨艺虹尹迪张珩
武汉工程大学绿色化工过程教育部重点实验室,湖北 武汉 430074
Author(s):
YANG Yihong YIN Di ZHANG Heng
Key Laboratory for Green Chemical Process of Ministry of Education,Wuhan institute of technology, Wuhan 430074, China
关键词:
抗肺动脉高压药物波生坦合成
Keywords:
pulmonary arterial hypertension drugbosentansynthesis
分类号:
O626.411
DOI:
103969/jissn16742869201212001
文献标志码:
A
摘要:
波生坦作为非选择性内皮激素受体拮抗剂,具有可以口服,耐受性较好的特点,能明显改肺动脉高压善患者的运动能力,提高患者的存活率.以5(2甲氧基苯氧基)丙二酸二乙酯为起始原料,经氯化、磺酰化、醚化得到波生坦.目标产物和中间体结构经IR、1HNMR、MS确认.采用单因素分析法确定了各步反应的最佳工艺条件,优化后反应的总收率可达71.5%.该工艺的氯化反应去除了缚酸剂,同时三氯氧磷的用量大幅度削减;磺酰化反应引入相转移催化剂,缩短了反应时间,提高了反应收率;醚化反应一步引入羟乙氧基,缩短了反应步骤,具有路线简捷、环保经济的特点.
Abstract:
Bosentan is an orally active dual endothelin (ET) receptor antagonist, can improve exercise capacity and survival in patients with pulmonary arterial hypertension. With 5(2methoxyphenyl)2(pyrimidin2yl)tetrahydropyrimidin 4,6dione as starting material, bosentan (1) was prepared by chlorination, sulfonylation and etherification,. The structures of target molecule and intermediates were confirmed by IR、1HNMR and MS . Using single factor analysis and the uniform design, the optimal reaction conditions of each reaction were obtained. The total yield was up to 71.5%. The chlorination reaction of this process gets rid of deacid reagent and uses less phosphorus oxychloride; phase transfer catalyst in sulfonylation reaction shortens reaction time and increases reaction yield; etherification reaction introduces hydroxyethoxy group only in one step, decreasing reaction steps. Therefore the process is concise, environmental friendly and economically.

参考文献/References:

[1]王勇,潘磊,石志华,等. 波生坦一线治疗特发性肺动脉高压的临床疗效及安全性评价\[J\].解放军医学杂志,2010,35(10):12451247.
[2]肖仁杰.波生坦治疗肺动脉高压药物的临床疗效\[J\]. 国际医药卫生导报,2012,18(9):12461247.
[3]杨宁,董俊军,刘克良.内皮素受体阻断剂波生坦的合成\[J\].中国药物化学杂志,2005,15(4):230233.
[4]Abhay G, Bindu M, Sandeep Mekde, et al. Process for preparing Bosentan: US, 20110039871A1\[P\]. 20110217.
[5]黄娇娇,张珩,杨艺虹,等.4,6二氯5(2甲氧基苯氧基)2,2’联吡啶的合成\[J\].合成化学,2011,19(6):809811.

相似文献/References:

备注/Memo

备注/Memo:
收稿日期:20121023作者简介:杨艺虹(1954 ),女,山东长清人,教授,硕士研究生导师.研究方向:药物合成及设计.
更新日期/Last Update: